Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) is a holding company. The Company, through its wholly owned subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar) and its variable interest entity (VIE) Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical), develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the People’s Republic of China. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) shares after opening at $2.15 moved to $2.43 on last trade day and at the end of the day closed at $2.33. Company price to sales ratio in past twelve months was calculated as 0.49 and price to cash ratio as 2.64. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) showed a negative weekly performance of -1.69%.
Retrophin Inc (NASDAQ:RTRX) CEO Martin Shkreli bought 4,000 shares of the stock in a transaction that occurred on Friday, March 14th. Retrophin, Inc. (NASDAQ:RTRX) shares advanced 7.09% in last trading session and ended the day on $18.72. Retrophin, Inc. (NASDAQ:RTRX) return on assets is -707.30%. Retrophin, Inc. (NASDAQ:RTRX) yearly performance is 294.11%.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) had its target price boosted by Needham & Company from $320.00 to $500.00 in a report issued on Tuesday, AR Network reports. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares moved up 6.83% in last trading session and was closed at $434.96, while trading in range of $403.03 – $438.66. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) year to date (YTD) performance is 537.02%.
Research analysts at Stifel Nicolaus started coverage on shares of Auspex Pharmaceuticals Inc (NASDAQ:ASPX) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $38.00 price target on the stock. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) weekly performance is 15.83%. On last trading day company shares ended up $34.61. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) distance from 50-day simple moving average (SMA50) is 36.60%. Analysts mean target price for the company is $35.25.